AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. GH
  4. [Form 4] Guardant Health, Inc. Insider Trading Activity

[Form 4] Guardant Health, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Form 4 filed for Guardant Health, Inc. (GH) details a routine equity award vesting by director Steve E. Krognes on 06/30/2025. Krognes converted 154 restricted stock units (RSUs)鈥攐riginally granted on 08/09/2022鈥攊nto the same number of common shares at a stated price of $0, reflecting a non-cash, in-kind issuance. Following the transaction, he directly owns 17,819 common shares and retains 1,852 unvested RSUs. The RSU grant vests monthly through 06/30/2026, and no shares were sold. The filing signifies ordinary executive compensation activity with no immediate balance-sheet or cash-flow impact on the company.

Il modulo 4 presentato da Guardant Health, Inc. (GH) descrive un normale vesting di premi azionari da parte del direttore Steve E. Krognes avvenuto il 30/06/2025. Krognes ha convertito 154 unit脿 azionarie vincolate (RSU)鈥攐riginariamente assegnate il 09/08/2022鈥攏ello stesso numero di azioni ordinarie a un prezzo nominale di $0, rappresentando un鈥檈missione in natura e non in denaro. Dopo la transazione, detiene direttamente 17.819 azioni ordinarie e mantiene 1.852 RSU non maturate. Il premio in RSU matura mensilmente fino al 30/06/2026 e nessuna azione 猫 stata venduta. La presentazione indica un鈥檃ttivit脿 ordinaria di compensazione esecutiva senza impatto immediato sul bilancio o sui flussi di cassa 诲别濒濒鈥檃锄颈别苍诲补.

El formulario 4 presentado por Guardant Health, Inc. (GH) detalla la adquisici贸n rutinaria de acciones por parte del director Steve E. Krognes el 30/06/2025. Krognes convirti贸 154 unidades restringidas de acciones (RSU)鈥攐torgadas originalmente el 09/08/2022鈥攅n el mismo n煤mero de acciones comunes a un precio declarado de $0, reflejando una emisi贸n en especie y sin efectivo. Tras la transacci贸n, posee directamente 17,819 acciones comunes y conserva 1,852 RSU no adquiridas. La concesi贸n de RSU se adquiere mensualmente hasta el 30/06/2026 y no se vendieron acciones. La presentaci贸n indica una actividad ordinaria de compensaci贸n ejecutiva sin impacto inmediato en el balance o flujo de caja de la empresa.

Guardant Health, Inc. (GH)鞚� Steve E. Krognes 鞚挫偓臧赌 2025雲� 6鞗� 30鞚�鞐� 鞝曣赴鞝侅溂搿� 欤检嫕 氤挫儊 甓岆Μ毳� 頄夓偓頃� 雮挫毄鞚� 雼挫潃 Form 4臧� 鞝滌稖霅橃棃鞀惦媹雼�. Krognes電� 2022雲� 8鞗� 9鞚�鞐� 攵�鞐悳 154臧滌潣 鞝滍暅 欤检嫕 雼渼(RSU)毳� 氇呺臧� $0鞐� 霃欖澕 靾橂焿鞚� 氤错喌欤茧 鞝勴櫂頄堨溂氅�, 鞚措姅 順勱笀鞚� 鞎勲媽 順勲 氚滍枆鞚� 鞚橂頃╇媹雼�. 鞚� 瓯半灅 頉� 攴鸽姅 歆侅爲 17,819欤检潣 氤错喌欤�毳� 氤挫湢頃橁碃 鞛堨溂氅� 1,852臧滌潣 氙疙檿鞝� RSU毳� 鞙犾頃橁碃 鞛堨姷雼堧嫟. RSU 攵�鞐姅 2026雲� 6鞗� 30鞚缄箤歆� 毵れ洈 甓岆Μ臧� 頇曥爼霅橂┌ 欤检嫕 毵る弰電� 鞐嗢棃鞀惦媹雼�. 頃措嫻 鞝滌稖鞚� 須岇偓鞚� 鞛鞝滍憸雮� 順勱笀 頋愲鞐� 歃夑皝鞝侅澑 鞓來枼鞚� 鞐嗠姅 鞚茧皹鞝侅澑 瓴届榿歆� 氤挫儊 頇滊彊鞛勳潉 雮橅儉雰呺媹雼�.

Le formulaire 4 d茅pos茅 pour Guardant Health, Inc. (GH) d茅taille une attribution d鈥檃ctions courante par le directeur Steve E. Krognes au 30/06/2025. Krognes a converti 154 unit茅s d鈥檃ctions restreintes (RSU)鈥攊nitialement attribu茅es le 09/08/2022鈥攅n un nombre 茅quivalent d鈥檃ctions ordinaires 脿 un prix d茅clar茅 de 0 $, refl茅tant une 茅mission en nature sans impact mon茅taire. Suite 脿 la transaction, il d茅tient directement 17 819 actions ordinaires et conserve 1 852 RSU non acquises. L鈥檃ttribution des RSU se lib猫re mensuellement jusqu鈥檃u 30/06/2026, et aucune action n鈥檃 茅t茅 vendue. Le d茅p么t signale une activit茅 de r茅mun茅ration ex茅cutive ordinaire sans impact imm茅diat sur le bilan ou les flux de tr茅sorerie de l鈥檈ntreprise.

Das f眉r Guardant Health, Inc. (GH) eingereichte Formular 4 beschreibt eine routinem盲脽ige Aktienaus眉bung durch den Direktor Steve E. Krognes am 30.06.2025. Krognes wandelte 154 Restricted Stock Units (RSUs)鈥攗rspr眉nglich am 09.08.2022 gew盲hrt鈥攝u demselben St眉ckzahl an Stammaktien zu einem angegebenen Preis von 0 $ um, was eine nicht zahlungswirksame Sachleistung darstellt. Nach der Transaktion besitzt er direkt 17.819 Stammaktien und h盲lt 1.852 nicht ausge眉bte RSUs. Die RSU-Zuteilung wird monatlich bis zum 30.06.2026 ausge眉bt, und es wurden keine Aktien verkauft. Die Einreichung signalisiert eine gew枚hnliche Verg眉tungsaktivit盲t des Managements ohne sofortige Auswirkungen auf Bilanz oder Cashflow des Unternehmens.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Small RSU vesting; no market impact.

The 154-share conversion is immaterial relative to Guardant Health鈥檚 ~100 million-share float. No open-market purchase or sale occurred, so supply鈥揹emand dynamics remain unchanged. Insider holdings edge slightly higher, supporting long-term alignment but offering no insight into near-term fundamentals. I view the disclosure as neutral for investors.

TL;DR: Routine equity award, governance neutral.

Monthly-vesting RSUs are typical for director compensation. The attorney-in-fact signature and timely filing meet Section 16 requirements, indicating sound compliance. Because no disposition occurred, there are no governance red flags. Impact on shareholder value is negligible.

Il modulo 4 presentato da Guardant Health, Inc. (GH) descrive un normale vesting di premi azionari da parte del direttore Steve E. Krognes avvenuto il 30/06/2025. Krognes ha convertito 154 unit脿 azionarie vincolate (RSU)鈥攐riginariamente assegnate il 09/08/2022鈥攏ello stesso numero di azioni ordinarie a un prezzo nominale di $0, rappresentando un鈥檈missione in natura e non in denaro. Dopo la transazione, detiene direttamente 17.819 azioni ordinarie e mantiene 1.852 RSU non maturate. Il premio in RSU matura mensilmente fino al 30/06/2026 e nessuna azione 猫 stata venduta. La presentazione indica un鈥檃ttivit脿 ordinaria di compensazione esecutiva senza impatto immediato sul bilancio o sui flussi di cassa 诲别濒濒鈥檃锄颈别苍诲补.

El formulario 4 presentado por Guardant Health, Inc. (GH) detalla la adquisici贸n rutinaria de acciones por parte del director Steve E. Krognes el 30/06/2025. Krognes convirti贸 154 unidades restringidas de acciones (RSU)鈥攐torgadas originalmente el 09/08/2022鈥攅n el mismo n煤mero de acciones comunes a un precio declarado de $0, reflejando una emisi贸n en especie y sin efectivo. Tras la transacci贸n, posee directamente 17,819 acciones comunes y conserva 1,852 RSU no adquiridas. La concesi贸n de RSU se adquiere mensualmente hasta el 30/06/2026 y no se vendieron acciones. La presentaci贸n indica una actividad ordinaria de compensaci贸n ejecutiva sin impacto inmediato en el balance o flujo de caja de la empresa.

Guardant Health, Inc. (GH)鞚� Steve E. Krognes 鞚挫偓臧赌 2025雲� 6鞗� 30鞚�鞐� 鞝曣赴鞝侅溂搿� 欤检嫕 氤挫儊 甓岆Μ毳� 頄夓偓頃� 雮挫毄鞚� 雼挫潃 Form 4臧� 鞝滌稖霅橃棃鞀惦媹雼�. Krognes電� 2022雲� 8鞗� 9鞚�鞐� 攵�鞐悳 154臧滌潣 鞝滍暅 欤检嫕 雼渼(RSU)毳� 氇呺臧� $0鞐� 霃欖澕 靾橂焿鞚� 氤错喌欤茧 鞝勴櫂頄堨溂氅�, 鞚措姅 順勱笀鞚� 鞎勲媽 順勲 氚滍枆鞚� 鞚橂頃╇媹雼�. 鞚� 瓯半灅 頉� 攴鸽姅 歆侅爲 17,819欤检潣 氤错喌欤�毳� 氤挫湢頃橁碃 鞛堨溂氅� 1,852臧滌潣 氙疙檿鞝� RSU毳� 鞙犾頃橁碃 鞛堨姷雼堧嫟. RSU 攵�鞐姅 2026雲� 6鞗� 30鞚缄箤歆� 毵れ洈 甓岆Μ臧� 頇曥爼霅橂┌ 欤检嫕 毵る弰電� 鞐嗢棃鞀惦媹雼�. 頃措嫻 鞝滌稖鞚� 須岇偓鞚� 鞛鞝滍憸雮� 順勱笀 頋愲鞐� 歃夑皝鞝侅澑 鞓來枼鞚� 鞐嗠姅 鞚茧皹鞝侅澑 瓴届榿歆� 氤挫儊 頇滊彊鞛勳潉 雮橅儉雰呺媹雼�.

Le formulaire 4 d茅pos茅 pour Guardant Health, Inc. (GH) d茅taille une attribution d鈥檃ctions courante par le directeur Steve E. Krognes au 30/06/2025. Krognes a converti 154 unit茅s d鈥檃ctions restreintes (RSU)鈥攊nitialement attribu茅es le 09/08/2022鈥攅n un nombre 茅quivalent d鈥檃ctions ordinaires 脿 un prix d茅clar茅 de 0 $, refl茅tant une 茅mission en nature sans impact mon茅taire. Suite 脿 la transaction, il d茅tient directement 17 819 actions ordinaires et conserve 1 852 RSU non acquises. L鈥檃ttribution des RSU se lib猫re mensuellement jusqu鈥檃u 30/06/2026, et aucune action n鈥檃 茅t茅 vendue. Le d茅p么t signale une activit茅 de r茅mun茅ration ex茅cutive ordinaire sans impact imm茅diat sur le bilan ou les flux de tr茅sorerie de l鈥檈ntreprise.

Das f眉r Guardant Health, Inc. (GH) eingereichte Formular 4 beschreibt eine routinem盲脽ige Aktienaus眉bung durch den Direktor Steve E. Krognes am 30.06.2025. Krognes wandelte 154 Restricted Stock Units (RSUs)鈥攗rspr眉nglich am 09.08.2022 gew盲hrt鈥攝u demselben St眉ckzahl an Stammaktien zu einem angegebenen Preis von 0 $ um, was eine nicht zahlungswirksame Sachleistung darstellt. Nach der Transaktion besitzt er direkt 17.819 Stammaktien und h盲lt 1.852 nicht ausge眉bte RSUs. Die RSU-Zuteilung wird monatlich bis zum 30.06.2026 ausge眉bt, und es wurden keine Aktien verkauft. Die Einreichung signalisiert eine gew枚hnliche Verg眉tungsaktivit盲t des Managements ohne sofortige Auswirkungen auf Bilanz oder Cashflow des Unternehmens.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Krognes Steve E.
(Last) (First) (Middle)
3100 HANOVER STREET
(Street)
PALO ALTO CA 94304
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/30/2025 M 154 A $0 17,819 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units $0 06/30/2025 M 154 (1) (2) Common Stock 154 $0 1,852 D
Explanation of Responses:
1. This represents a restricted stock unit award granted on August 9, 2022 that vested 25% of the shares subject to such award on June 30, 2023. The remaining 75% of the shares subject to such award vests in substantially equal installments on each monthly anniversary of June 30, 2023 during the three-year period thereafter.
2. Not applicable for Restricted Stock Units.
Remarks:
/s/ John Saia, as attorney-in-fact for Steve Krognes 07/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What did Guardant Health (GH) report in the latest Form 4?

Director Steve E. Krognes converted 154 RSUs into common stock on 06/30/2025.

How many Guardant Health shares does Steve Krognes now own?

Post-transaction, he directly holds 17,819 common shares plus 1,852 unvested RSUs.

Was any cash exchanged in the 06/30/2025 transaction?

No. The RSU conversion price was $0; it was a non-cash issuance.

Does the Form 4 indicate any share sales by the director?

No shares were sold; the filing records only an acquisition via vesting.

When will the remaining RSUs granted on 08/09/2022 fully vest?

They vest in equal monthly installments through 06/30/2026.
Stock GH logo
Guardant Health

NASDAQ:GH

GH Rankings

#1093 Ranked by Market Cap
N/A Ranked by Dividends

GH Latest News

Aug 15, 2025
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 4, 2025
American Cancer Society and Guardant Health Partner to Expand Cancer Screening Access and Advance Health Equity
Jul 31, 2025
Guardant Health to Participate in the Canaccord Genuity 45th Annual Growth Conference
Jul 30, 2025
Guardant Health Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
Jul 30, 2025
Guardant Health and James Van Der Beek Team Up to Raise Awareness About New Advances in Colorectal Cancer Screening for Adults 45+

GH Latest SEC Filings

Aug 6, 2025
[Form 4] Guardant Health, Inc. Insider Trading Activity
Aug 4, 2025
[Form 4] Guardant Health, Inc. Insider Trading Activity
Jul 30, 2025
[10-Q] Guardant Health, Inc. Quarterly Earnings Report
Jul 30, 2025
[8-K] Guardant Health, Inc. Reports Material Event
Jul 18, 2025
[Form 4] Guardant Health, Inc. Insider Trading Activity

GH Stock Data

7.30B
118.23M
4.5%
99.25%
7.7%
Diagnostics & Research
Services-medical Laboratories
United States
PALO ALTO